KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana

Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Therapeutics, Inc. (the “Company”) (NasdaqCM: KTRA) and TuHURA Biosciences, Inc. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair to Kintara shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ktra/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240405944592/en/

The Kintara Therapeutics Stock at the time of publication of the news with a fall of -12,89 % to 0,143USD on NYSE stock exchange (05. April 2024, 02:00 Uhr).